REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

REGENXBIO (Nasdaq: RGNX) reported positive long-term Phase I/II RGX-202 functional data for Duchenne, with treated patients improving an average of 7.4 NSAA points versus cTAP at 18 months (n=4) and 6.6 points at 12 months.

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) reported positive long-term Phase I/II RGX-202 functional data for Duchenne, with treated patients improving an average of 7.4 NSAA points versus cTAP at 18 months (n=4) and 6.6 points at 12 months. The company expects pivotal topline data in early Q2 2026 and plans a mid-2026 BLA filing under accelerated approval while continuing confirmatory enrollment. REGENXBIO also highlighted an FDA PDUFA date of Feb 8, 2026 for RGX-121, a $100M AbbVie milestone tied to sura-vec first patient dosing, and in-house manufacturing readiness from its Rockville facility.

Positive

• RGX-202 showed +7.4 NSAA points vs cTAP at 18 months
• Pivotal topline data expected early Q2 2026
• Planned mid-2026 BLA submission under accelerated pathway
• FDA PDUFA date set for Feb 8, 2026 for RGX-121
• $100 million milestone from AbbVie upon first DR patient dosing
• Completed process performance qualification lots for RGX-202

Negative

• Regulatory approvals remain pending, including FDA decisions in 2026
• Confirmatory trial enrollment not complete at time of BLA filing
• Commercial launches contingent on multiple successful 2026 readouts

Argus Session date unavailable

+3.36% session move Open Argus

Details

News Market Reaction – RGNX

The recorded move for RGNX in the trading session of this news was +3.36%.

Data tracked by StockTitan Argus. Session date unavailable.

Key Figures

AFFINITY DUCHENNE Phase I/II n: 4 patients NSAA improvement vs cTAP (18M): 7.4 points NSAA improvement vs cTAP (12M): 6.6 points +5 more

AFFINITY DUCHENNE Phase I/II n

4 patients

Pivotal dose cohort with 18-month functional follow-up

NSAA improvement vs cTAP (18M)

7.4 points

RGX-202 pivotal dose patients at 18 months vs cTAP model

NSAA improvement vs cTAP (12M)

6.6 points

RGX-202 pivotal dose patients at 12 months vs cTAP model

Pivotal trial enrollment

30 patients

AFFINITY DUCHENNE pivotal trial completed enrollment in Oct 2025

RGX-121 PDUFA date

February 8, 2026

FDA decision timing for clemidsogene lanparvovec (MPS II)

Top-line RGX-202 data

Early Q2 2026

Pivotal RGX-202 Duchenne trial top-line readout timing

AbbVie milestone

$100 million

Payment on first patient dosed in DR Phase IIb/III trial, expected 1H 2026

Sura-vec wet AMD topline

Q4 2026

ATMOSPHERE and ASCENT pivotal trials, subretinal delivery

Historical Context

5 past events · Latest: Dec 18

5 events

1. Dec 18

   Conference presentation

   24h Move

   +2.6%

   Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference.

2. Nov 25

   Investor conference

   24h Move

   +10.0%

   Participation in Piper Sandler 37th Annual Healthcare Conference with fireside chat.

3. Nov 06

   Earnings report

   24h Move

   -3.8%

   Q3 2025 financials plus timelines for RGX-202, RGX-121 PDUFA, and sura-vec trials.

4. Oct 30

   Clinical progress

   24h Move

   -0.2%

   Completion of pivotal RGX-202 enrollment and initiation of commercial production.

5. Oct 29

   Earnings call notice

   24h Move

   -2.4%

   Scheduling of Q3 2025 results conference call and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase i/ii, biologics license application (bla), pdufa, priority review voucher (prv), +4 more

8 terms

phase i/ii medical

"New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect"

"Phase I/II" describes early stages of testing a new medicine or treatment, where researchers first evaluate its safety and then begin to see if it works. For investors, these phases are important because they indicate whether a product is progressing toward potential approval and commercialization, which can impact future value and success prospects. These stages help gauge how close a new treatment is to reaching the market.

biologics license application (bla) regulatory

"submit a Biologics License Application (BLA) under the accelerated approval pathway"

A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.

pdufa regulatory

"FDA PDUFA target date is February 8, 2026."

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

priority review voucher (prv) regulatory

"FDA approval would result in receipt of a Priority Review Voucher (PRV)"

A priority review voucher (PRV) is a transferable regulatory 'fast pass' that speeds up a government agency’s review of a drug or medical product, shortening the time it takes to get approval. For investors, a PRV is a valuable asset because it can both accelerate a product’s path to market—potentially bringing revenue sooner—and be sold to other companies, creating a direct one-time or strategic financial benefit.

aav gene therapies medical

"pipeline of AAV gene therapies for rare and retinal diseases."

AAV gene therapies use a harmless, naturally occurring virus (adeno-associated virus) as a delivery truck to carry a working copy of a gene into a patient’s cells, aiming to correct or replace a faulty gene. Investors watch these therapies because they can offer long-lasting, sometimes one-time treatments that command high prices and royalties, but they also carry manufacturing challenges, safety and regulatory risk, and large upfront development costs that affect a company’s value.

suprachoroidal delivery medical

"trial of sura-vec for DR using suprachoroidal delivery."

Suprachoroidal delivery is a method of putting drugs or therapies into the thin space between two layers at the back of the eye, placing medicine close to retinal tissues without spreading it throughout the whole eye. For investors, it matters because this targeted approach can increase effectiveness, lower side effects, and extend how long a treatment works, which can make ophthalmic products more competitive, safer, and commercially attractive.

subretinal delivery medical

"pivotal trials of sura-vec using subretinal delivery in Q4 2026."

A surgical method that places a drug, gene therapy or cell treatment directly into the tiny space beneath the light-sensitive layer at the back of the eye (the retina). Think of it like slipping medicine under a delicate wallpaper so it reaches the exact spot that needs repair. Investors care because this delivery route can improve effectiveness, affect safety and complexity, and therefore influence clinical success, manufacturing costs, regulatory reviews and market potential.

ind readiness regulatory

"The Company is approaching IND readiness for the treatment of geographic atrophy"

IND readiness describes how prepared a drug developer is to file an Investigational New Drug (IND) application with a regulator, which is the formal request to begin human clinical trials. Investors care because it marks the transition from lab work to testing in people — like a car being cleared for a long road trip — and a successful filing can unlock regulatory milestones, clear development timelines, and increase the program’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months 
• Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-year
• Expecting FDA PDUFA decision and multiple pivotal top-line data readouts in 2026 to support potential commercial launches 2026-2028
• In-house manufacturing and strategic global partnerships driving commercial readiness
• Presentation at 44th Annual J.P. Morgan Healthcare Conference Wednesday, January 14

ROCKVILLE, Md., Jan. 11, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. 

"2026 is set to be a transformative year for REGENXBIO, as we enter commercial stage with two near-term catalysts from our three late-stage assets and a clear path to sustained growth," said Curran Simpson, President and CEO, REGENXBIO. "We are starting the year with exciting new long-term data for our Duchenne program, demonstrating how our comprehensive strategy to maximize the potential for therapeutic benefit across all our programs is resulting in positive outcomes for patients. We are continuing to set the bar high for how potentially life-changing gene therapies are discovered, developed, and manufactured; this year we are sharply focused on advancing our commercial readiness to enable successful launches of these medicines for patients in need.

CLINICAL PROGRAM UPDATES AND 2026 ANTICIPATED MILESTONES 

RGX-202 for Duchenne Muscular Dystrophy
New Functional Data

• REGENXBIO today announced new, positive 18-month functional data from patients treated with the pivotal dose in the Phase I/II portion of the AFFINITY DUCHENNE^® trial (n=4). All patients exceeded expected disease trajectory on the North Star Ambulatory Assessment (NSAA) using the established cTAP disease progression model. RGX-202 recipients improved an average of 7.4 points compared to cTAP. These same patients improved an average of 6.6 points compared to cTAP at 12 months post-treatment. The Company plans to share additional Phase I/II safety, biomarker, and functional data at the MDA Clinical and Scientific Conference in March 2026.

Clinical Trial and Regulatory Milestones

• REGENXBIO expects to share pivotal topline data in early Q2 2026 and submit a Biologics License Application (BLA) under the accelerated approval pathway in mid-2026. Following the completion of enrollment in the pivotal trial (n=30) in October 2025, the Company continues to enroll in the confirmatory trial and expects to have majority of this trial enrolled at the time of BLA filing.
• Regulatory interactions with the FDA and European Medical Association (EMA) are planned for 1H 2026, supporting the global expansion of the AFFINITY DUCHENNE^® trial.

Clemidsogene lanparvovec (RGX-121) for MPS II, also known as Hunter syndrome

• FDA PDUFA target date is February 8, 2026. FDA approval would result in receipt of a Priority Review Voucher (PRV), to which REGENXBIO has full rights.
• Partner Nippon Shinyaku, with its U.S. subsidiary NS Pharma, is prepared to commercialize clemidsogene lanparvovec following potential approval. REGENXBIO plans to lead the clinical and commercial manufacturing its in-house Manufacturing Innovation Center in Rockville, Md.

Surabgene lomparvovec (sura-vec, ABBV-RGX-314) for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR)
Sura-vec is being developed in collaboration with AbbVie, and could be the first gene therapy for a non-rare disease, if approved.

• Sura-vec is on track to be the first gene therapy for wet AMD. REGENXBIO expects top-line data from ATMOSPHERE^® and ASCENT^® pivotal trials of sura-vec using subretinal delivery in Q4 2026.
• REGENXBIO will initiate a two-part sham injection-controlled Phase IIb/III trial of sura-vec for DR using suprachoroidal delivery. The Company will receive a $100 million milestone payment from AbbVie upon first patient dosed, expected 1H 2026.

Leading Gene Therapy Capabilities 
REGENXBIO is one of the only gene therapy companies with fully in-house, end-to-end capabilities from capsid engineering and discovery through commercial-ready manufacturing, designed to reliably scale supply and realize the blockbuster potential of its gene therapy portfolio. At the REGENXBIO Manufacturing Innovation Center, in Rockville, Md., REGENXBIO expects to continue to build supply intended for potential commercial launches. Process performance qualification lots have been completed for RGX-202.

REGENXBIO continues to expand the therapeutic potential of AAV gene delivery through capsid discovery and engineering. The Company is approaching IND readiness for the treatment of geographic atrophy using a new capsid that has demonstrated higher transgene expression via suprachoroidal delivery to the eye.

J.P. Morgan Healthcare Conference Presentation
President and CEO Curran Simpson will present at the J.P Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PT. A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA^®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.

FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2024, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Zolgensma^® is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.

CONTACTS: 
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com 

George E. MacDougall
Investor Relations
IR@regenxbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional-outcomes-in-lead-duchenne-gene-therapy-program-302657988.html

SOURCE REGENXBIO Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did REGENXBIO (RGNX) report for RGX-202 Duchenne functional data?

RGX-202 patients improved an average of 7.4 NSAA points vs cTAP at 18 months (n=4) and 6.6 points at 12 months.

When does REGENXBIO expect pivotal RGX-202 topline data and BLA timing for RGNX?

The company expects pivotal topline data early Q2 2026 and plans to submit a BLA under accelerated approval in mid-2026.

What is the FDA timeline for REGENXBIO's RGX-121 (RGNX)?

RGX-121 has an FDA PDUFA target date of February 8, 2026.

How much milestone funding will REGENXBIO receive from AbbVie related to sura-vec (RGNX)?

REGENXBIO will receive a $100 million milestone payment from AbbVie when the first DR patient is dosed, expected in 1H 2026.

Is REGENXBIO ready to support commercial manufacturing for RGNX therapies?

The company cites in-house commercial manufacturing capability at its Rockville facility and completed process performance qualification lots for RGX-202.

What are the key 2026 risks for RGNX investors?

Key risks include pending regulatory decisions, the need for positive pivotal readouts, and confirmatory trial enrollment and outcomes before potential launches.